BACKGROUND: Non-melanoma skin cancer (NMSC) is the most common malignancy in humans. Targeted therapy with monoclonal antibody cetuximab is an option in case of advanced tumor or metastasis.
Introduction
Non-melanoma skin cancer (NMSC) is the most common malignancy in humans, with basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC) as the dominant tumor types [1] . As major risk factors the following findings could be identified: age ≥ 50 years of life, Fitzpatrick's phototype I or II, and increased chronic exposure to natural or artificial ultraviolet (UV) irradiation. Other known risk factors include immunosuppression, solid organ transplantation, and use of tanning beds [1] [2] [3] [4] [5] [6] .
Logically, the reduction of UV-exposure seems the major goal in primary prevention [1] . The three pillars of current treatment for localized disease are surgery with wide excision, Mohs surgery for recurrent tumors or special localizations such as the face, and radiotherapy [1] . Cetuximab is a chimeric monoclonal antibody against epidermal growth factor receptor (EGFR) and had been FDA-approved for head and neck SCC in conjunction with radiotherapy [12] .
We present and update of the use of cetuximab in NMSC searching PUBMED 2011-2017.
BCC
BCC is the most common human cancer. Age-adjusted BCC incidence (cases per 100,000 person-years) was 360.0 in men and 292.9 in women in a recent population-based study in Olsmedt county, Missouri [13] . In contrast to cSCC, BCC does not increase cancer-related mortality [14] . BCC develops as a result of the interplay between ultraviolet radiation (UVR) and genotype with somatic mutations (Smoothed) and germline mutations/polymorphisms. The role of UVR exposure and BCC is not as clear as in cSCC [15] . 
Cutaneous SCC
Cutaneous SCC (cSCC) is the second most common NMSC. The age-adjusted cSCC incidence (cases per 100,000 person-years) has been calculated as high as 207.5 for men and 128.8 for women in Olmsted country [13] . The rate of metastasis has been estimated between 1.9 to 2.6%.
Risk factors for metastatic spread are the maximum diameter, poor histological differentiation and particular anatomical localizations such as lip, cheek, and ear [16] .
The risk of recurrence, metastases, and mortality can be further stratified. High-risk and very high-risk tumors are the possible indication for the use of cetuximab.
High-risk tumors (HRSCC) are characterized by localization in the head-and-neck region, maximum diameter of more than 2 cm, invasion into the subcutaneous adipose tissue, poor differentiation, recurrence or occurrence in a previously irradiated area, and immunosuppression [16] .
Very high-risk SCC (VHRSCC) include tumors with perineural, lympho-vascular, parotid, cartilaginous or bony invasion, in-transit, regional or distant metastases [17] .
Studies of cetuximab in cutaneous SCC

2011-17
In 2011, the first phase II trial included 36 patients with SCC. Disease control was obtained in 69% after 6 weeks of treatment. Patients received a 400 mg/m 2 loading dose followed by 250 mg/m 2 weekly for at least 6 weeks with 48 weeks follow-up. In this study, three related serious adverse events were observed -two grade 4 infusion reactions and one grade 3 interstitial pneumonitis. Grade 1 to 2 acne-like rash occurred in 78% of patients and was associated with prolonged PFS [18] . 
Cetuximab in advanced BCC 2011-2017
Cetuximab has also been used in patients with advanced BCC [11] . The safety profile is not different from SCC patients. However, Karapurakal et al. (2015) Two patients achieved a CR, the other 2 had a PR. During a median follow-up of 12 months overall survival was 100%. Mean disease-free survival was one month. Three of their four patients suffered from Gorlin-Goltz syndrome [22] .
Management of adverse effects
Skin toxicity is the most common adverse effects of cetuximab. Treatment is based on skin moisturizers and sunscreens [28] . In a retrospective trial on gastrointestinal cancer patients, prophylactic and reactive treatment for acne-like rash was equally effective [29] .
Treatment of the papulopustular rash includes topical use of erythromycin or metronidazole for mild cases, and systemic tetracyclines or retinoids for skin toxicities grade ≥2 with temporary interruption of cetuximab therapy [30] . The incidence of skin toxicity seems to be lower in smokers but the incidence of anorexia is higher compared to non-smokers [31] .
Topical vitamin K3 (menadione) is not effective in the prevention of cutaneous toxicity nor does it change the expression of EGFR in skin [32] .
In conclusion, there are increasingly more data available on the use of targeted therapy in advanced NMSC although controlled prospective, randomized, placebo-controlled phase III trials are still missing. From the available data, cetuximab seems to be effective as monotherapy after surgery. The safety profile is not different from approved indications such as advanced colorectal and head-and-neck cancer. In contrast to hedgehog inhibitor vismodegib approved for advanced BCC, second cSCC have not been observed with cetuximab therapy of NMSC [33] [34] [35] [36].
